TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 03/14/22

Glenview Capital Management’s 13F portfolio value decreased from $5.46B to $4.69B this quarter. The number of positions decreased from 59 to 57. They increased Global Payments and Coca Cola Euro Partners while dropping Paramount Global and Takeda. The top three stakes are T...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and former market darlings. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helpi...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2022 Q3 earnings call. For further details see: Takeda Pharmaceutical Company Limited 2022 Q3 - Results - Earnings Call Presentation

Takeda Pharmaceutical Company Limited. (TAK) Q3 2022 Earnings Conference Call February 3, 2022 6:00 am ET Corporate Participants Christopher O’Reilly - Global Head, IR & Global Finance Christophe Weber - President and Chief Executive Officer Andy Plump - President Research and Deve...

Glenview Capital Management’s 13F portfolio value decreased from $5.96B to $5.46B this quarter. The number of positions decreased from 64 to 59. They increased Baxter International and Uber Technologies while decreasing ViacomCBS and dropping Walgreens Boots Alliance. The t...

My portfolio, built specifically for my retirement ~20+ years from now, rides the November volatility in the market as this year's Santa run begins amidst COVID fears. Rivian finally IPOs as I add shares of this EV monster to hopefully follow in the footsteps of Tesla as America's aut...

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November

My portfolio, built specifically for my retirement ~20+ years from now, rides the September downturn in the market back under $400k. Some massive risk-on portfolio restructuring including more Bitcoin as I prepare for the seasonal Santa Claus and Bitcoin run. Making monthly contri...